What is the main business of Ardigen?

The main business activity of Ardigen focuses on other research and experimental development on natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on November 12, 2015.

Where is the headquarters located?

The headquarters is located at: ul. Leona Henryka Sternbacha 1, 30-394 Kraków.

Who is on the management board?

The management board includes: Janusz Stanisław Homa (President of the Management Board), Łukasz Paweł Nowak (Member of the Management Board), and Michał Warchoł (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 287,563 (approx. $77,678).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

How much revenue was generated?

The company reported a revenue of $11,802,305 in 2024, which is a decrease of 5.9% compared to 2023.

Yes, in 2024 the company was profitable, achieving a net profit of $1,067,652, meaning the company increased its profit by 96.3%.

What is the largest operating cost?

The largest operating cost category falls under external services. This category amounted to $5,937,860 in 2024, representing 57% of all operating expenses.

ArdigenS.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2015-11-12

Share capital

287 563,00 PLN

Activity description

Ardigen is an AI-powered CRO focused on drug discovery and precision medicine. It develops custom AI algorithms and models, including LLM-based drug discovery and foundational models for biology. The company serves biotech and pharmaceutical clients and has completed more than 520 projects for over 100 customers.

Registered address

ul. Leona Henryka Sternbacha 1, 30-394 Kraków, Poland

Website

ardigen.com

Phone

Social media

Electronic delivery address

AE:PL-73662-78063-CIBHC-18

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 12.51mMedianUSD 126.89kAverageUSD 4.67m

Net profit

This companyUSD 879.21kMedianUSD -19.64AverageUSD 371.62k

Operating costs

This companyUSD 11.03mMedianUSD 165.83kAverageUSD 4.01m

Assets

This companyUSD 10.45mMedianUSD 251.40kAverageUSD 7.40m

Industry

Bank accounts

Registered as a VAT taxpayer on 2015-11-17. Active

Bank Pekao SA
19 1240 4432 1978 0011 2896 3950
Bank Pekao SA
38 1240 4432 1789 0011 2897 2864
Bank Pekao SA
43 1240 4432 1111 0011 2895 9823

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication date	Event
Dec 4, 2015	Commercial Companies Code notice

Public aid

15 public aid cases recorded, with a total value of $7,743,871.

Grant date	Purpose	Gross amount	Granting body
Apr 3, 2024	Aid for research and development projects: industrial research	$229,557	Dyrektor Narodowego Centrum Badań i Rozwoju
Sep 28, 2021	Aid for research and development projects: industrial research	$1,391,810	Dyrektor Narodowego Centrum Badań i Rozwoju
Sep 28, 2021	Aid for research and development projects: experimental development	$167,200	Dyrektor Narodowego Centrum Badań i Rozwoju

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $6,626,620.

Start	Project	EU co-financing	Programme
2021-07-01	Opracowanie technologii Microbiome Biomarker Discovery Platform pozwalającej odkrywać metodami sztucznej inteligencji kandydatów na biomarkery predykcyjne pochodzenia MIKROBIOMOWEGO do przewidywania skuteczności terapii onkologicznych, w szczególności ICT (a-PD-1, CTLA-4) oraz chemioterapii.	$1,559,010	Program Operacyjny Inteligentny Rozwój
2020-08-01	Stworzenie INNOWACYJNEJ, opartej na sztucznej inteligencji TECHNOLOGII TCRact w celu wprowadzenia na rynek NOWEJ USŁUGI polegającej na projektowaniu IN SILICO receptorów limfocytów T (TCR) do wykorzystania w immunoterapiach nowotworów.	$3,000,641	Program Operacyjny Inteligentny Rozwój
2017-12-01	Opracowanie technologii A.I.mmune tworzenia bioinformatycznego komponentu testów diagnostycznych stosowanych w immunoterapii nowotworów.	$855,708	Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020

Tenders

No recorded participation in tenders.

Authorized Representatives

Elżbieta Kokoć — Attorney-in-fact (joint)

Livia Gorini Legg — Management Board Member

Janusz Stanisław Homa — President of the Management Board

Łukasz Paweł Nowak — Management Board Member

Michał Warchoł — Management Board Member

Manner of representation

The company is represented by two members of the management board acting jointly, or one member of the management board together with a commercial proxy.

Supervisory board

Bogusław Stanisław Sieczkowski — Supervisory Board Member

Krzysztof Daniel Brzózka — Supervisory Board Member

Tomasz Marek Piętka — Supervisory Board Member

Paweł Tadeusz Przewięźlikowski — Supervisory Board Member

Beneficial owners

Person	Rights
Janusz Stanisław Homa (55)	Shareholder of a joint-stock company, 17.14%; Beneficjent rzeczywisty sprawuje pośrednią kontrolę nad spółką poprzez podmiot homa fundacja rodzinna w organizacji, nad którym sprawuje kontrolę (jako fundator oraz prezes zarządu fundacji). fundacja posiada 62 500 akcji (w tym 13 000 uprzywilejowanych serii a), co daje jej 75 500 głosów, stanowiących 19,74% ogólnej liczby głosów w spółce.

Person

Rights

Janusz Stanisław Homa (55)

Shareholder of a joint-stock company, 17.14%; Beneficjent rzeczywisty sprawuje pośrednią kontrolę nad spółką poprzez podmiot homa fundacja rodzinna w organizacji, nad którym sprawuje kontrolę (jako fundator oraz prezes zarządu fundacji). fundacja posiada 62 500 akcji (w tym 13 000 uprzywilejowanych serii a), co daje jej 75 500 głosów, stanowiących 19,74% ogólnej liczby głosów w spółce.

Competitors

Name	Revenue	Website
KCRS.A.	$43,596,034.97	kcrcro.com
Scope FluidicsS.A.	$3,082,936.61	scopefluidics.com
IntodnaS.A.	$2,286,118.76	intodna.com

Change history

Date	Event
2024-08-02	Address change (Ul. Podole 76, 30-394, Kraków → Ul. Leona Henryka Sternbacha 1, 30-394, Kraków)
2020-09-01	Share capital change (277,066.00 PLN → 283,132.00 PLN)
2020-03-04	Share capital change (268,232.00 PLN → 277,066.00 PLN)
2019-04-24	Address change (Ul. Prof. Michała Bobrzyńskiego 14, 30-348, Kraków → Ul. Podole 76, 30-394, Kraków)
2019-01-25	Share capital change (254,832.00 PLN → 268,232.00 PLN)

FAQ

Last updated: 2026-09-02